SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic

	Research Index \| Publishers \| My Account \| Contact Us \| About MindBranch
	Welcome Guest (Login/Register) \| 0 items

Advanced Search > | Tips >

Contact a
Research Assistant
US 800-774-4410
or +1-240-747-3094
Search Assistance >

SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis

Published Date: June 2009

Published By: Decision Resources

Page Count: 25

Order Code: R55-649

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Table of Contents

Similar
Products

Executive Summary: Strategic Considerations; Stakeholder Implications
Introduction
Overview of Juvenile Idiopathic Arthritis: Subtypes of Juvenile Idiopathic Arthritis; Diagnosis of Juvenile Idiopathic Arthritis
Epidemiology: Overview; Disease Definition; Methods
Current Treatment Approaches: Nonsteroidal Anti-Infl ammatory Drugs; Corticosteroids; Methotrexate; Tumor Necrosis Factor-Alpha Inhibitors; Kineret; Orencia; Rituxan
Emerging Therapies for Juvenile Idiopathic Arthritis: Regeneron’s Arcalyst; Novartis’s Canakinumab; Roche/Chugai’s Actemra
Opportunities in the Treatment of Juvenile Idiopathic Arthritis: Outlook for JIA Treatments; Ongoing Unmet Needs in Juvenile Idiopathic Arthritis
Bibliography
Tables: 1. Juvenile Idiopathic Arthritis Disease Subtypes; 2. Number of Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis in the Major Pharmaceutical Markets, 2008-2018; 3. Classification Criteria for the Various Definitions of Juvenile Idiopathic Arthritis; 4. Tumor Necrosis Factor-Alpha Inhibitors Used in the Treatment of Juvenile Idiopathic Arthritis; 5. Emerging Agents in Juvenile Idiopathic Arthritis
Figures: 1. Treatment Algorithms for Subtypes of Juvenile Idiopathic Arthritis

Similar Products

• Prostate Cancer Drug Discoveries: What the Future Holds

Published Nov 2009 by Espicom Healthcare Intelligence

• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)

Published Nov 2009 by La Merie S.L.

• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)

Published Nov 2009 by La Merie S.L.

• Competitor Analysis: FGF-R Agonists and Antagonists

Published Nov 2009 by La Merie S.L.

• BI for Drug Development: Oracle Introduces Clinical Development Analytics

Published Nov 2009 by IDC

• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis

Published Nov 2009 by Aruvian's R'search

• Competitor Analysis: TGF-R Agonists and Antagonists

Published Nov 2009 by La Merie S.L.

• Protein Kinase Therapeutics in Oncology - Where to Commercialize?

Published Oct 2009 by BioSeeker Group AB

• CDK Inhibitors Patent Landscape 2009

Published Oct 2009 by France Innovation Scientifique et Transfer

• Antidiabetics in Australia Market Forecast

Published Oct 2009 by Datamonitor

Privacy Policy | Terms & Conditions | Site Map | Return Policy | Help FAQs

Copyright © 1999-2008, All Rights Reserved, MindBranch.com

Phone: 800-774-4410 (US) or +1-240-747-3094 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: support@mindbranch.com